152 related articles for article (PubMed ID: 20235796)
1. Pharmacogenomics in the treatment of inflammatory bowel disease.
Smith MA; Marinaki AM; Sanderson JD
Pharmacogenomics; 2010 Mar; 11(3):421-37. PubMed ID: 20235796
[TBL] [Abstract][Full Text] [Related]
2. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics and IBD: TPMT and thiopurines.
Sandborn WJ
Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S35-7. PubMed ID: 15168829
[No Abstract] [Full Text] [Related]
4. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of inflammatory bowel disease.
Kelleher D; Farrell R; McManus R
Novartis Found Symp; 2004; 263():41-53; discussion 53-6, 211-8. PubMed ID: 15669633
[TBL] [Abstract][Full Text] [Related]
8. [Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine].
Bessard G; Hardy G; Chartier A; Stanke-Labesque F
Therapie; 2004; 59(1):71-5. PubMed ID: 15199672
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of inflammatory bowel disease.
Katsanos KH; Papadakis KA
Pharmacogenomics; 2014 Dec; 15(16):2049-62. PubMed ID: 25521361
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of inflammatory bowel disease therapies.
Sandborn WJ; Faubion WA
Curr Gastroenterol Rep; 2000 Dec; 2(6):440-5. PubMed ID: 11079044
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics in inflammatory bowel disease.
Egan LJ; Derijks LJ; Hommes DW
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):21-8. PubMed ID: 16431300
[TBL] [Abstract][Full Text] [Related]
13. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
15. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of azathioprine products.
Baker DE
Rev Gastroenterol Disord; 2003; 3(4):219-23. PubMed ID: 14668694
[TBL] [Abstract][Full Text] [Related]
17. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
Seidman EG
Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
[TBL] [Abstract][Full Text] [Related]
18. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine.
Nguyen TM; Le Gall C; Lachaux A; Boulieu R
Int J Clin Pharmacol Ther; 2010 Apr; 48(4):275-81. PubMed ID: 20353749
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of thiopurines in inflammatory bowel disease.
Derijks LJ; Wong DR
Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
